Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1936-0541
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B ; day:24 ; month:10 ; year:2020 ; pages:1-12
Hepatology international ; (24.10.2020), 1-12
- Creator
-
Huang, Yi-Wen
Hsu, Chao-Wei
Lu, Sheng-Nan
Yu, Ming-Lung
Su, Chien-Wei
Su, Wei-Wen
Chien, Rong-Nan
Hsu, Ching-Sheng
Hsu, Shih-Jer
Lai, Hsueh-Chou
Qin, Albert
Tseng, Kuan-Chiao
Chen, Pei-Jer
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12072-020-10098-y
- URN
-
urn:nbn:de:101:1-2020121001224296114819
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Huang, Yi-Wen
- Hsu, Chao-Wei
- Lu, Sheng-Nan
- Yu, Ming-Lung
- Su, Chien-Wei
- Su, Wei-Wen
- Chien, Rong-Nan
- Hsu, Ching-Sheng
- Hsu, Shih-Jer
- Lai, Hsueh-Chou
- Qin, Albert
- Tseng, Kuan-Chiao
- Chen, Pei-Jer
- SpringerLink (Online service)
Other Objects (12)
Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks
Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2
Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
Zur Behandlung der Haarzell-Leukämie mit rekombinantem Interferon alfa-2b
Ropeginterferon alfa-2b (Polycythaemia vera) : Nutzenbewertung gemäß § 35a SGB V
α-2-HS-glycoprotein is a potential marker predicting hepatitis B e antigen seroconversion in patients with chronic hepatitis B during treatment with pegylated interferon alfa-2b
Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system
Safety evaluation of PEGylated MNPs and p-PEGylated MNPs in SD rats
Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment
Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks
Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2
Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
Zur Behandlung der Haarzell-Leukämie mit rekombinantem Interferon alfa-2b
Ropeginterferon alfa-2b (Polycythaemia vera) : Nutzenbewertung gemäß § 35a SGB V
α-2-HS-glycoprotein is a potential marker predicting hepatitis B e antigen seroconversion in patients with chronic hepatitis B during treatment with pegylated interferon alfa-2b
Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system
Safety evaluation of PEGylated MNPs and p-PEGylated MNPs in SD rats
Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment
Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks
Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2
Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
Zur Behandlung der Haarzell-Leukämie mit rekombinantem Interferon alfa-2b
Ropeginterferon alfa-2b (Polycythaemia vera) : Nutzenbewertung gemäß § 35a SGB V
α-2-HS-glycoprotein is a potential marker predicting hepatitis B e antigen seroconversion in patients with chronic hepatitis B during treatment with pegylated interferon alfa-2b
Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system
Safety evaluation of PEGylated MNPs and p-PEGylated MNPs in SD rats